NVL-655 is under clinical development by Nuvalent and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT). According to GlobalData, Phase II drugs for Inflammatory Myofibroblastic Tumor (IMT) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NVL-655 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVL-655 overview
NVL-655 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC), cholangiocarcinoma, neuroblastoma, anaplastic large cell lymphoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, renal cell carcinoma, breast cancer, inflammatory myofibroblastic tumor (IMT), colorectal cancer, ovarian cancer, papillary thyroid cancer and soft-tissue sarcoma. It acts by targeting anaplastic lymphoma kinase (ALK). It is administered through oral route.
Nuvalent overview
Nuvalent is a biopharmaceutical company that discovers and develop novel drug candidates to treat cancer. It investigates its pipeline programs including NVL-520, a novel brain-penetrant ROS1-selective inhibitor; and NVL-655, an ALK-selective inhibitor for the treatment of non-small cell lung cancer (NSCLC). It is also evaluating multiple discovery-stage research programs in the area of oncology. Nuvalent develop small molecules to minimize adverse events and address brain metastases. The company works in collaboration with medical institutions, CROs and CMOs to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NVL-655’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
